Centiva Capital LP Invests $404,000 in Phreesia, Inc. (NYSE:PHR)

Centiva Capital LP bought a new position in Phreesia, Inc. (NYSE:PHR - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 16,057 shares of the company's stock, valued at approximately $404,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Bosun Asset Management LLC bought a new stake in Phreesia during the 4th quarter valued at $267,000. BNP Paribas Financial Markets bought a new stake in Phreesia during the 4th quarter valued at about $163,000. Ameriprise Financial Inc. purchased a new position in shares of Phreesia during the fourth quarter valued at approximately $269,000. Algert Global LLC increased its holdings in Phreesia by 190.1% during the fourth quarter. Algert Global LLC now owns 77,833 shares of the company's stock valued at $1,958,000 after buying an additional 51,006 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC boosted its holdings in Phreesia by 41.2% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 484,617 shares of the company's stock worth $12,193,000 after buying an additional 141,411 shares during the period. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on PHR shares. KeyCorp cut their target price on Phreesia from $30.00 to $28.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 16th. Piper Sandler reiterated an "overweight" rating and issued a $33.00 target price (up from $31.00) on shares of Phreesia in a research report on Wednesday, January 29th. Needham & Company LLC reaffirmed a "buy" rating and set a $29.00 price objective on shares of Phreesia in a research report on Thursday, March 13th. Canaccord Genuity Group boosted their target price on Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a research note on Thursday, March 13th. Finally, DA Davidson reduced their price target on Phreesia from $36.00 to $34.00 and set a "buy" rating for the company in a report on Monday, April 14th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $31.33.

Insider Transactions at Phreesia

In other news, General Counsel Allison C. Hoffman sold 1,213 shares of Phreesia stock in a transaction that occurred on Wednesday, April 16th. The stock was sold at an average price of $23.81, for a total value of $28,881.53. Following the completion of the transaction, the general counsel now owns 137,921 shares in the company, valued at approximately $3,283,899.01. This trade represents a 0.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Evan Roberts sold 16,005 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $30.00, for a total transaction of $480,150.00. Following the completion of the sale, the chief operating officer now directly owns 748,302 shares of the company's stock, valued at $22,449,060. The trade was a 2.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 111,640 shares of company stock worth $3,094,167. Company insiders own 5.80% of the company's stock.

Phreesia Price Performance

Shares of NYSE:PHR traded up $0.05 during trading on Tuesday, reaching $26.10. The stock had a trading volume of 382,595 shares, compared to its average volume of 435,477. The business has a fifty day moving average price of $25.12 and a 200-day moving average price of $24.83. Phreesia, Inc. has a 1-year low of $17.07 and a 1-year high of $30.53. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. The stock has a market cap of $1.53 billion, a PE ratio of -17.75 and a beta of 0.74.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.